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AntimicrobialHuman apolipoprotein A–I (apoA–I) is a 28 kDa protein and a major component of high-density lipoproteins,
mediating several essential metabolic functions related to heart disease. In the present study the potential
protective role against bacterial pathogens was explored. ApoA–I suppressed bacterial growth of Escherichia coli
and Klebsiella pneumoniae. The protein was able to bind lipopolysaccharides and showed a strong preference for bi-
layer vesicles made of phosphatidylglycerol over phosphatidylcholine. Lysine side chains of apoA–I were acetylated
to evaluate the importance of electrostatic forces in the binding interaction with both membrane components.
Electrophoresis properties, dot blot analysis, circular dichroism, and ﬂuorescence spectroscopy to probe for changes
in protein structure indicated that the acetylated protein displayed a strongly reduced lipopolysaccharide and
phosphatidylglycerol binding. A mutant containing only the N-terminal domain of apoA–I also showed a reduced
ability to interact with the membrane components, although to a lesser extent. These results indicate the potential
for apoA–I to function as an antimicrobial protein and exerts this function through lysine residues.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
High-density lipoproteins (HDL) play a central role in reverse
cholesterol transport, mediating the efﬂux of cholesterol from the
peripheral tissues to the liver for metabolism and excretion [1]. In
addition to the anti-atherogenic properties, HDL is recognized for
playing a role in the innate immune response against pathogens.
Evidence suggests that HDL is directly involved in several steps of
the primary immune response pathway, serving a critical role in
defending the host organism against viral, bacterial, and parasitic in-
fections [2–4]. Speciﬁcally, apolipoprotein A–I (apoA–I), the main
protein component of HDL, inhibits cell fusionmediated by HIV glyco-
proteins to host cells and HDL, suppresses bacterial growth and pro-
tects against bacterial infections in vivo [2,3,5]. HDL also possesses
anti-inﬂammatory properties in response to lipopolysaccharides
(LPS), the endotoxic component found in the outer membrane of
gram-negative bacteria. Both in vivo and in vitro studies have indicated
a positive correlation between HDL levels and protection against
bacterial endotoxemia. Intravenous administration of reconstitutedte; apoA–I, apolipoprotein A–I;
U, colony forming units; HDL,
PC, phosphatidylcholine; PG,
UV, large unilamellar vesicles;
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rights reserved.HDL protected rats and mice against lethal doses of LPS [6,7]. Further-
more, in human clinical trials, treatment with exogenous reconstituted
HDL results in diminished endotoxic effects upon exposure to LPS [8]. It
is suggested that HDL particles neutralize LPS activity directly through
partitioning of the toxic lipid A region into the lipidmonolayer of the li-
poprotein or indirectly by associating with lipopolysaccharide binding
protein [6,9].
Among the different lipoprotein classes, HDL displays the greatest
anti-microbial activity and LPS binding afﬁnity [3,10]. Variations in
bactericidal activity and anti-inﬂammatory responses between HDL,
low-density and very low-density lipoproteins have led to the inves-
tigation into the role of lipoprotein-associated apolipoproteins. Sev-
eral studies have reported that apoA–I is directly involved in the
protection against bacterial infections and LPS toxicity. Treatment of
gram-negative bacteria cultures with apoA–I suppresses cell growth,
resulting in a reduced colony count [11]. In vitro studies have shown
that apoA–I can directly associate with LPS, thereby rendering it
biologically inactive [12]. Furthermore, animals injected with LPS
pre-incubated with apoA–I have signiﬁcantly decreased mortality
rates compared to their counterparts treated solely with LPS [13].
Although the ability of apoA–I to exert anti-microbial activity and
neutralize endotoxins has been documented, the speciﬁc molecular
interactions involved are still poorly understood. In the present
study, we have focused on the binding interaction of apoA–I with
LPS and phosphatidylglycerol (PG). These negatively charged mem-
brane components of the outer and inner bacterial membrane may
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To test this hypothesis, we modiﬁed the apoA–I lysine residues
through acetylation and investigated its binding afﬁnity to LPS and
PG. In addition, to locate potential binding sites on apoA–I, binding
studies were carried out with a deletion mutant comprised of the
N-terminal domain of apoA–I.
2. Materials and methods
2.1. Site-directed mutagenesis, protein expression, puriﬁcation and
sample preparation
The apoA–I C-terminal deletion mutant, apoA–IΔ190–243, was
constructed by introducing a stop codon at amino acid position
Ala 190 using the following primers: 5 -GGGGCCCGCCTGTAGGAGT
ACCACGCC-3 and 5 -GGCGTGGTACTCCTACAGGCG GGCCCC-3 . The
mutant construct (in the pET-20b(+) expression vector) was gener-
ated by polymerase chain reaction using a QuikChange-II site-
directed mutagenesis kit (Agilent Technologies). The deletion of
the C-terminal residues (Δ190-243) was veriﬁed by DNA sequenc-
ing (Genewiz). Recombinant apoA–I bearing a 6xHis-tag was
over-expressed in Escherichia coli BL21 (DE3) pLysS cells (Agilent
Technologies), and induced with 0.5 mM IPTG at 37 °C for 3.5 h.
Cells were collected by centrifugation at 8000 g for 15 min (Sorvall
RC5C Plus). Cells were resuspended in phosphate buffered saline
(PBS; 150 mM NaCl, 10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4)
and lysed by sonication using a digital soniﬁer (Branson) in ﬁve
30 s increments at 30% amplitude. Sonicated samples were subjected
to two rounds of centrifugation at 20,000 g for 30 min at 4 °C to
remove cell components. Supernatant was mixed with equal parts
(v/v) of loading buffer (2× PBS, 6 M guanidine-HCl, pH 7.4) and
puriﬁed using 5 mL capacity Hi-trap chelating columns (GEHealthcare).
Proteins were eluted using elution buffer (500 mM imidazole in PBS)
pH 7.4 and dialyzed against 4 L of 10 mM ammonium bicarbonate,
1 mM EDTA with 3 additional buffer changes within 48 h. Proteins
were further puriﬁed by size-exclusion chromatographyusing Superdex
200 resin in a XK-26/70 column (GE Healthcare). Prior to experimenta-
tion, proteinswere dissolved in 6 M guanidine-HCl and dialyzed against
2 L of PBS at 4 °C with three additional buffer changes within 48 h.
2.2. Modiﬁcation of apoA–I lysine residues
Recombinant wild-type (WT) apoA–I was dissolved in PBS to a
ﬁnal concentration of 0.5 mg/mL and mixed with an equal volume
of saturated sodium acetate. Excess acetic anhydride was added in
four equal parts every 15 min and mixed on ice for 1 h, followed by
an additional mixing for 20 min. Modiﬁed proteins were dialyzed
against PBS. ApoA–I samples were extensively dialyzed against
10 mM ammonium bicarbonate, 1 mM EDTA and subsequently ly-
ophilized. The mass of the apoA–I samples was determined using
MALDI-TOF (4800 MALDI TOF/TOF Analyzer, AB SCIEX) at the
IIRMES facility at CSU Long Beach. Proteins were dissolved in
sinapinic acid in 0.1% TFA and 50% acetonitrile.
2.3. Electrophoresis
For each apoA–I variant, 10 μg of protein was incubated at 70 °C
for 10 min with lithium dodoceyl sulfate sample loading buffer
(Invitrogen). Samples were run on a NuPAGE 10% Bis-Tris gel
(Invitrogen) at a constant 200 V for 35 min using MES SDS running
buffer. For non-denaturing electrophoresis experiments, 20 μg of pro-
tein was incubated at 37 °C with varying amounts of LPS serotype
O55:B5 (Sigma Aldrich) for 1 h and subsequently cooled to ambient
temperature prior to loading onto the gel. Samples were run on
4–20% gradient Tris-glycine gels (Invitrogen) at a constant 125 V for
120 min. Gels were stained using 0.5% (m/v) naphthol blue-blackin 10% glacial acetic acid, 45% methanol (v/v) for 30 min, and sub-
sequently destained overnight in 10% glacial acetic acid and 45%
methanol.
2.4. Dot blot analysis
Immuno-dot blotting analysis was performed using a Bio-Dot
microﬁltration dot-blot apparatus (Bio-Rad). Nitrocellulosemembranes
were pre-soaked in Tris buffered saline (TBS, 20 mMTris–HCl, 150 mM
NaCl, pH 7.5). Unused wells were sealed off with tape to ensure proper
vacuum. Sample wells were ﬁlled with 100 μL TBS and drained. LPS
(50 μL of 10 ng/μL in PBS) was absorbed onto the nitrocellulose mem-
brane. Unoccupied sites were blocked using 300 μL of 1% bovine
serum albumin (BSA) in Tween-TBS (0.05% Tween-20 in TBS) and sub-
sequently washed twice with 200 μL Tween-TBS. ApoA–I in a range of
0.1 to 1 μg was added to each sample well in triplicate. Unbound pro-
teins were washed three times with 200 μL of Tween-TBS. Goat anti-
human apoA–I HRP conjugated antibody (100 μL diluted 2000-fold in
1% BSA, Tween-TBS; Abcam, Cambride, MA) was added to each sample
well. Wells were subsequently washed three times with 200 μL
Tween-TBS, and 200 μL TBS to remove excess Tween. To each sample
well 40 μL of Amersham ECL Plus Western Blotting Detection Reagent
(GE Healthcare) was added, followed by 40 μL of deionized water.
Bound apoA–I was visualized using Kodak BioMax XAR-2 autoradiogra-
phy ﬁlm with a 5 min exposure time. Films were imaged using Gel Doc
XR and Quantity One software (Bio-Rad). Spot intensity on the image
was determined using Image Lab software (Bio-Rad) by creating
masks of equal size for each spot and the intensity of each spot was
quantiﬁed. The average background intensity of control spots (no LPS
or no apoA–I) was subtracted from the reported spot intensity values
for treatments.
2.5. Circular dichroism
ApoA–I samples (0.25 mg/mL in 20 mM sodium phosphate buffer,
pH 7.3) were incubated in the absence or presence of LPS at a 1:2 or
1:1 LPS-protein mass ratio. The ellipticity was measured between
185 and 260 nm in a Jasco 810 polarimeter using a cuvette with a
1 mm path length. Plots are the average of four scans, measured at
a scanning rate of 50 nm/min. Ellipticity values were converted to
molar ellipticity by the following equation:
θ½  ¼ MRW θλð Þ=dc
θλ is the observed ellipticity (in degrees), d is the pathlength (cm), c
is the protein concentration (g/mL), and MRW is the mean residue
weight. The α-helical content was determined by using the following
equation in which [θ]222 nm is the molar ellipticity at 222 nm [14]:
% α−helix ¼ 100• − θ½ 222 nm þ 3;000
 
= 39;000ð Þ
For guanidine–HCl denaturation analysis, apoA–I samples in a
concentration of 0.2 mg/mL were incubated overnight at a given de-
naturant concentration in order to attain equilibrium, and ellipticity
was measured at 222 nm.
2.6. Fluorescence spectroscopy
To measure exposed hydrophobic surfaces, apoA–I was incubated
in the presence of 8-anilinonaphthalene-1-sulfonate (ANS; Sigma-
Aldrich). Fifty micrograms apoA–I (dissolved in PBS) was pre-
incubated with LPS (E. coli O55:B5, Sigma-Aldrich) in a 1:2 or 1:1
LPS-protein mass ratio for 15 min at 37 °C. ANS was prepared as a
stock solution of 250 mM, and added to the mixture (2.5 mM ﬁnal
concentration) and incubated for another 15 min at 37 °C. ANS ﬂuo-
rescence was measured using a Perkin-Elmer LS-55 Fluorescence
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were excited at a wavelength of 395 nm and the emission spectrum
was measured from 400 to 600 nm (4 nm excitation and emission slit
width) at 37 °C. All measurements were done in triplicate. For trypto-
phan ﬂuorescence analysis, 50 μg apoA–I was preincubated with LPS
(1:2 and 1:1 LPS-protein mass ratio) for 30 min at 37 °C in PBS. Trypto-
phan was excited at 295 nm to minimize the contribution of tyrosine
residues present in apoA–I. The emission spectrum was measured
from 300 to 450 nm using an excitation and emission slit width of
3.5 nm at 37 °C, and all measurements were done in triplicate.
2.7. Calcein release
Five milligrams of egg phosphatidylglycerol (PG) or egg phospha-
tidylcholine (PC) (Avanti Polar Lipids Inc.) was dissolved in 0.5 mL
3:1 chloroform/methanol (v/v) in phosphate-free glass tubes washed
with Contrad 70 (Decon Labs). The phospholipids were dried with a
stream of N2 gas and placed in a vacuum freeze dryer for 24 h. The
lipid ﬁlm was then suspended in Tris–HCl buffer (20 mM Tris–HCl,
150 mM NaCl, 0.5 mM EDTA, pH 7.4) containing 100 mM calcein
(Sigma-Aldrich). After rigorous vortexing for 1 min, the lipid suspen-
sion was extruded with a Mini-Extruder (Avanti Polar Lipids Inc) at
45 °C through a membrane with a pore size of 100 nm to form
large unilamellar vesicles (LUV) with encapsulated calcein. LUVs
were separated from free calcein using a PD-10 desalting column
(GE Healthcare). Phospholipid concentrations were determined
using the Ames phosphate assay [15]. Changes in the ﬂuorescence
emission intensity, resulting from membrane leakage of entrapped
calcein, was measured using a LS 55 Fluorescence Spectrometer
(PerkinElmer). Excitation and emission wavelength were set at 490
and 520 nm, respectively (5 nm slit width). LUVs (10 μM) were
equilibrated for 2 min in a 1 mL cuvet containing Tris–HCl buffer at
37 °C, after which the protein was added at varying lipid-protein
molar ratios (10:1–10,000:1), which corresponded to 1 μM–1 nM
protein. The ﬂuorescence emission intensity was monitored for an-
other 8 min, after which 10 μl of a 1% Triton X-100 solution was
added to determine the maximum calcein release. The percentage
of protein-mediated calcein release from the vesicles was deter-
mined using the following equation:
% calcein release ¼ 100• Ip−Ib
 
= Imax−Ibð Þ
Ip is the maximum ﬂuorescence intensity caused by the addition of
protein, Ib is the background ﬂuorescence intensity before addition
of protein (just prior to the 2 min mark), Imax is the ﬂuorescence in-
tensity after detergent was added (10 min). Each experiment was
conducted at least three times to generate the mean value ± stan-
dard deviation.
2.8. Antimicrobial assay
E. coli (ATCC Number: 9637) or Klebsiella pneumoniae (ATCC
Number: 13883) were cultured in liquid luria broth (LB; Fisher
Scientiﬁc) for 12 h (37 °C, 225 rpm). While in the log-phase of
growth, cells were diluted to an OD600 of 0.02 in LB, the diluted
cells transferred to individual wells of a 96-well plate (Falcon) and
further diluted 9:10 with apoA–I protein or BSA (0.4 mg/ml). Cells
were cultured in the presence of test proteins for 1 h at 37 °C in a
humidiﬁed chamber. Subsequently, cells were placed at 4 °C, serially
diluted in PBS (Fisher Scientiﬁc) and 50 μl of each dilution plated on
LB agar plates in duplicate or triplicate. The plates were subsequently
incubated (37 °C for 16–20 h) and the colonies counted. The relative
colony forming units (CFU) for each treatment was calculated using the
following formula: Relative CFU = ((number of CFU in a treatment) /
(average number of CFU in the BSA treatment) ∗ 100). Error valuesare standard error of themean (SEM). Aminimum of duplicate samples
were prepared for each treatment and the results show the combined
data of at least three experiments conducted on different days.
3. Results
3.1. Modiﬁcation of apoA–I
Lysine residues may play a critical role in the interaction of apoA–I
with bacterial membrane components thereby exerting antibacterial
activity. Lipopolysaccharides are anchored in the outer leaﬂet of the
outer membrane, while the inner membrane bilayer is rich in anionic
phospholipids such as PG [16]. To study this in detail, apoA–I was
modiﬁed: the 21 positively charged ε-amino side chains of lysine
were acetylated by acetic anhydride. It has been suggested that
apoA–I adopts a two-domain structure [17]. The C-terminal domain
(amino acid residues 190 to 243) contains 6 lysine side-chains and
can be removed without disrupting the helix bundle stability [18].
This offers an opportunity to investigate if the N-terminal domain of
the protein exerts similar LPS and PG binding properties compared
to the full length protein, or that the C-terminal harbors potential
binding sites for LPS and PG. Acetylation of apoA–I was analyzed by
SDS-PAGE, showing a small decrease in electrophoretic mobility,
resulting from an increase in mass from 30.3 kDa (WT apoA–I) to
32.1 kDa of the acetylated protein (Fig. 1A). In addition, the acetylated
protein was stained with decreased intensity, as amido black may pref-
erentially bind to positively charged amino acid side chains. This result
indicated that apoA–I was acetylated (referred to as ac-apoA–I), after
which the degree of modiﬁcation was calculated based on MALDI-TOF
analysis. The mass shifted from 29,668 Da for WT apoA–I to 30,483 Da
for ac-apoA–I, an increase of 815 Da which can account for 19.4
acetylations (42 Da increase per acetylation) (Fig. 1B), indicating that
most of the 21 lysine residues in apoA-I were acetylated (92.3 %). The
C-terminal deletion mutant (apoA–IΔ190–243) was obtained by site-
directedmutagenesis, and after expression and puriﬁcation the deletion
was conﬁrmed by SDS–PAGE (mass of 22.4 kDa, Fig. 1A) and MALDI-
TOF (23,780 Da, expected mass 23,611 Da).
3.2. LPS binding interaction
Binding of apoA–I to LPS was initially determined by changes
in the electrophoretic mobility of apoA–I when subjected to non-
denaturing PAGE. ApoA–I appears as a heterogeneous band at the
top portion of the gel, which indicates the presence of oligomers. Ad-
dition of LPS to apoA–I led to a gradual disappearance of the original
apoA–I bands, while new bands appeared at the lower portion of the
gel. The increased mobility on PAGE indicates that apoA–I formed a
complex with LPS (Fig. 2A). The complex may have an increased net
negative charge because of the phosphate moieties on LPS. The in-
creased mobility of ac-apoA–I compared to WT apoA–I in the absence
of LPS is likely caused by the neutralization of lysine side chains
which decreased the theoretical pI from 5.27 to 4.24 (Fig. 2B). In
addition, the single band of ac-apoA-I indicates it may favor a mono-
meric state. In contrast to WT apoA–I, the position and staining inten-
sity of ac-apoA–I did not change upon LPS addition, indicative of
decreased LPS binding. Mobility and staining changes upon addition
of LPS to apoA–I Δ190–243 were observed, but compared to the
wild-type protein more LPS was required (Fig. 2C). This indicates
that the deletion mutant was still able to bind to LPS, but less
efﬁciently than WT apoA–I. To further investigate this difference in
LPS binding, dot blot analysis was performed. Membranes with
LPS absorbed were incubated with the three protein variants. This
showed that the ac-apoA–I dot was signiﬁcantly less intense
compared WT apoA–I (Fig. 3A and B). This result indicates a decrease
in LPS binding activity of ac-apoA–I and is in agreement with the
electrophoresis analysis. The intensity of apoA–I Δ190–243 was also
Fig. 1. Analysis of apoA–I variants. Panel A shows the SDS-PAGE analysis of WT apoA–I (lane 1), ac-apoA–I (lane 2), and apoA–IΔ190-243 (lane 3). Panel B: MALDI-TOF analysis of
WT apoA–I (m/z 29,668) and ac-apoA–I (m/z 30,483).
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experiments showed that the spot intensity was proportional to the
amount of apoA–I (Fig. 3C).
The Far-UV CD spectrum of WT apoA–I is characteristic for an
α-helical protein with troughs at 208 and 222 nm (Fig. 4). The lysine
modiﬁcation of apoA–I caused a modest decrease in the α-helical
content, from 59 to 43% (Table 1). The midpoint of guanidine induced
denaturation was 0.92 ± 0.04 M for WT and 0.91 ± 0.05 M for
ac-apoA–I, indicating that acetylation did not affect the stability of
the protein. ApoA–IΔ190–243 also displayed a reduced α-helical con-
tent. Thus, while the proteins lost some of their helical content, they
retained their overall α-helical character and stability. Addition of
LPS to apoA–I caused a signiﬁcant reduction in molar ellipticity
(Fig. 4), resulting in a decrease in α-helical content from 59 to 42%
(2:1 protein/LPS mass ratio) or 40% (1:1 protein/LPS mass ratio).
This result indicated that LPS binding resulted in a change in the
structural organization of apoA–I. On the other hand, the molar ellip-
ticity of ac-apoA–I remained essentially unchanged upon LPS addi-
tion. Similar to the WT protein, LPS addition to apoA–IΔ190–243
caused a reduction in the helical content (Table 1).
ANS typically binds to exposed hydrophobic pockets on proteins,
evident by a large increase in ﬂuorescence intensity and a substantial
blue-shift in the wavelength of maximum emission (λmax) [19,20].Fig. 2. Non-denaturing PAGE of apoA–I variants in the absence or presence of LPS. Panel A
absence of LPS are shown in lane 1. Lanes 2–4: 20 μg apoA–I pre-incubated with 4 μg (laneSince changes in secondary structure were observed upon LPS bind-
ing, this may also lead to changes in apoA–I ANS binding sites. Control
incubations of LPS with ANS showed that ANS ﬂuorescence intensity
did not change, indicating that ANS did not bind to LPS (data not
shown). However, ANS ﬂuorescence was strongly increased upon in-
cubation with apoA–I, concomitant with a blue-shift in λmax from 511
to 480 nm. The ANS ﬂuorescence intensity in the presence of apoA–I
was further increased upon incubation with LPS (Fig. 5). This indi-
cates an increased number of ANS binding sites on apoA–I induced
by the presence of LPS. ANS ﬂuorescence intensity was less intense
for ac-apoA–I (Table 1). In contrast to the unmodiﬁed protein, ANS
ﬂuorescence intensity remained virtually unchanged when LPS was
incubated with ac-apoA–I. LPS addition to apoA–IΔ190–243 resulted
in an increase in the ANS ﬂuorescence intensity, indicating that the
deletion mutant retained the ability to bind to LPS.
ApoA–I bears four tryptophan residues at positions 8, 50, 72 and
108, all located in the N-terminal domain of the protein. The trypto-
phan ﬂuorescence intensity of apoA–I was ~500 (arbitrary units)
with a λmax of 348 nm, indicating that the average environment of
the tryptophan residues is polar. Incubation with LPS resulted in a
2 nm red-shift, with an increased ﬂuorescence intensity to 623
(Fig. 6). The tryptophan ﬂuorescence intensity of ac-apoA–I was
substantially lower, and no change was observed in either λmax or: WT apoA–I; panel B: ac-apoA–I; panel C: apoA–IΔ190–243. Proteins (20 μg) in the
2), 10 μg (lane 3), and 20 μg LPS (lane 4).
Fig. 3. Dot blot analysis of apoA–I binding to LPS. A and B: 0.5 μg LPS was loaded onto the nitrocellulose membrane followed by addition of 1 μg of apoA–I. Sample analysis was
performed in triplicate for each of the apoA–I variants and LPS control. 1) LPS in the absence of apoA–I; 2) WT apoA–I; 3) ac-apoA–I; 4) apoA–IΔ190–243. The spot intensity is
shown in panel B (arbitrary units). C: Spot intensity as a function of apoA–I concentration (0.5 μg LPS).
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incubations in the absence and presence of LPS showed a modest
increase in the ﬂuorescence intensity (Table 1).3.3. ApoA–I binding to PC and PG vesicles
Negatively charged phospholipids such as PG are abundantly
present in membranes of gram-negative bacteria. To investigate
the ability to interact with negatively charged membranes, calcein
was incorporated in PG vesicles at 100 mM concentration at which
the ﬂuorophore is highly quenched. Protein binding to the LUV sur-
face may then result in packing defects in the phospholipid bilayer,
and calcein is released in the surrounding buffer. The diluted concen-
tration of calcein in buffer causes it to ﬂuoresce strongly at 520 nm.
The ability of apoA–I to release calcein from PG vesicles was then
compared to PC vesicles. The release of calcein from PG vesicles
(10 μM) by apoA–I was >90% at protein concentrations between 1
and 0.033 μM. Further dilution of apoA–I reduced the activity but
even dilution to a concentration of 1 nM apoA–I was still able to
trigger a ~40% release (Fig. 7). In contrast, when calcein was incorpo-
rated into LUVs made of PC, an abundant phospholipid in eukaryotic
cell membranes, the activity was strongly reduced: 1 μM apoA–I re-
leased 38% of calcein, thus 1000 times more protein was required
to release a similar amount of calcein from PC membranes comparedFig. 4. Effect of LPS on the secondary structure of WT apoA–I. Far UV circular dichroism
scan of apoA–I in the absence and presence of LPS. Shown are WT apoA–I (____),
WT apoA–I + LPS (⋅⋅⋅⋅⋅⋅⋅), ac-apoA–I (— —) and ac-apoA–I + LPS (— ⋅ — ⋅).to PGmembranes. This result indicated that apoA–I has a strong pref-
erence for PG membranes compared to PC membranes.
To assess the ability of the apoA–I variants to release calcein from PG
membranes, 3.3 ng protein was used (lipid to protein molar ratio of
3000:1), a concentration that allows for the measurement of changes
in calcein release. After equilibrating a 10 μM suspension of PG vesicles
containing calcein for 2 min, apoA–I was added resulting in a rapid in-
crease in ﬂuorescent intensity and thus release of calcein (Fig. 8). Addi-
tion of detergent at 8 min released calcein from the remaining
non-lysed vesicles. ApoA–I was able to release 80.1 ± 2.4 % of encapsu-
lated calcein, but calcein release was reduced to 25.9 ± 0.70 for
ac-apoA–I and 57.3 ± 3.6% for apoA–IΔ190–243.3.4. Antibacterial activity of apoA–I
Antibacterial activity was analyzed by assessing bacterial growth
of the gram-negative bacteria E. coli and K. pneumoniae (Fig. 9). The
relative number of CFU for E. coli and K. pneumoniae incubated in
the presence of apoA–I protein was reduced relative to cells treated
with BSA (57.2 ± 3.1% and 63.8 ± 3.9%, respectively), demonstrating
that apoA–I is an antibacterial protein. E. coliwas moderately, but not
signiﬁcantly, more sensitive than K. pneumoniae to apoA–I. The
antibacterial activity of apoA–I was attenuated when the protein
was acetylated as measured by the increased relative number of
CFU for E. coli and K. pneumoniae incubated in the presence of
ac-apoA–I (81.6 ± 6.5 % and 99.8 ± 7.1 %, respectively), suggesting
that positively charged lysine residues of apoA–I play a critical role
in the antibacterial activity. Of note, acetylation of apoA–I decreased
the antibacterial activity in tests of K. pneumoniae. The C-terminalTable 1
ANS and tryptophan ﬂuorescence, and circular dichroism analysis of apoA-I and
variants in the presence or absence of LPS.
ANS ﬂuorescence Tryptophan
ﬂuorescence
Circular
dichroism
Protein Protein:
LPS ratio
λmax
(nm)
Intensity λmax
(nm)
Intensity α-helical
content
WT apoA-I 1:0 478 143 ± 4 348 499 ± 38 59.2 ± 0.4%
2:1 469 188 ± 6 349 613 ± 90 42.3 ± 0.1%
1:1 462 202 ± 18 350 623 ± 67 40.1 ± 0.3%
ac-apoA-I 1:0 482 48 ± 4 348 203 ± 26 43.3 ± 1.6%
2:1 482 57 ± 4 348 205 ± 32 43.6 ± 1.9%
1:1 482 55 ± 2 348 204 ± 24 41.4 ± 0.5%
apoA-I
Δ190-243
1:0 482 63 ± 2 350 469 ± 65 41.9 ± 1.8%
2:1 477 102 ± 2 350 553 ± 59 34.4 ± 3.1%
1:1 475 134 ± 5 350 540 ± 78 32.7 ± 4.7%
Fig. 5. Effect of LPS on the ANS binding to LPS. Shown are the ANS ﬂuorescence emission
intensity (arbitrary units) between 400 and 600 nm in the presence ofWT apoA–I (____)
and a 1:1 (mass) mixture of WT apoA–I with LPS (⋅⋅⋅⋅⋅⋅⋅), ac-apoA–I (— —), and
ac-apoA–I + LPS (— ⋅ — ⋅).
Fig. 7. ApoA–I-induced calcein release from PG and PC vesicles. A 10 μM suspension of
PG vesicles (●) or PC vesicles (○) was incubated with various concentrations of WT
apoA–I (1 μM−1 nM, molar lipid to protein ratio of 10:1–10,000:1) after which the %
of calcein was determined by the change in ﬂuorescence intensity at 520 nm.
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antibacterial activity against E. coli or K. pneumoniae (94.9 ± 9.0%
and 88.5 ± 2.6% of controls, respectively).
4. Discussion
Human apoA–I is a 28 kDa single polypeptide composed of 243
amino acid residues. It is composed of amphipathic α-helices, and
circular dichroism analysis estimated an overall helical content of
50–57% [21]. ApoA–I is a highly ﬂexible protein, allowing it to exist
in lipid-free, lipid-poor (pre β HDL) and lipid-rich states (spherical
HDL) [22]. Extensive structural analysis suggests that apoA–I is
composed of two independently folded domains, consisting of an
N-terminal helix bundle (residues 1–189) and a loosely structured
C-terminal domain (residues 190–243) [17,23]. The C-terminal do-
main displays high lipid binding afﬁnity, and possibly initiates lipid
binding to attach apoA–I to the lipid surface [24]. However, other
studies suggested that the N-terminal helix can also act as a lipid
anchor [25]. The C-terminal domain of apoA-I has been identiﬁed as
the site for the self-associating properties of the protein [24]. This
structural and functional organization bears similarities with that of
human apoE [26].Fig. 6. Tryptophan ﬂuorescence emission scan. ApoA–I samples were excited at
295 nm and the emission monitored between 300 and 450 nm (arbitrary units).
Shown are WT apoA–I (____), WT apoA–I in the presence of LPS (⋅⋅⋅⋅⋅⋅⋅), ac-apoA–I (— —)
and ac-apoA–I + LPS (— ⋅— ⋅).Gram-negative bacterial membranes are composed of an outer
membrane with LPS protruding from the outer leaﬂet, and an inner
membrane rich in PG [27,28]. Both membrane components are poten-
tial targets for antimicrobial proteins, and in the current study we
investigated the role of lysine residues and the contribution of the
C-terminal domain on the ability of apoA–I to interact with these bac-
terial membrane components. Based on extensive analysis of antimi-
crobial proteins and peptides, it is generally recognized that the
following properties are attributed with effective protection against
gram-negative bacterial pathogens: 1) high cationic residue content
and 2) large hydrophobic regions, typically oriented in an amphipathic
motif [29,30]. Thus exchangeable apolipoproteinswith the amphipathic
α-helix as a signature feature for mediating lipid binding have the po-
tential to function as antimicrobial proteins. For example, ﬁsh apoA–I
has been recognized as an antimicrobial protein, human apoE is effec-
tive in neutralizing a potentially lethal dose of LPS, and insect apolipo-
protein, apolipophorin III (apoLp-III), is able to associate with LPS and
bacterial membranes [31–35].
In the present study it was shown that incubation of two gram-
negative bacteria strains in the presence of WT apoA–I signiﬁcantly
suppressed bacterial growth, resulting in reduced colony counts.
On the other hand, ac-apoA–I and apoA–I Δ190–243 displayed
attenuated bacterial growth suppression. Although minor, differences
in bacteriostatic effects between E. coli and K. pneumoniaemay be due,Fig. 8. Calcein release from PG vesicles by apoA–I variants. Vesicles (10 μM) were
equilibrated for 2 min. ApoA–I (3.3 nM, 3000:1 PG-protein molar ratio) was added at
2 min to calcein-ﬁlled PG vesicles and the ﬂuorescence intensity monitored until
10 min at which the remaining vesicles were lysed by addition of Triton X-100.
Fig. 9. Antibacterial activity of apoA–I of E. coli or K. pneumoniae. Anti-microbial activity
was analyzed by assessing bacterial growth of log-phase gram-negative bacteria in the
presence of apoA–I (white bars), ac-apoA–I (light gray bars) and apoA–I Δ190-243
(dark gray bars). Colony counts were relative to BSA (100%) and were signiﬁcantly
reduced in the presence of apoA–I (57% and 64% CFU, respectively). The potency of
apoA–I to reduce bacterial growth was signiﬁcantly decreased after acetylation
(82% and 100% CFU) or removal of the C-terminal end (95% and 89%). E. coli unpaired
t-test: WT vs. ac-apoA–I (P = 0.0020, t = 3.849, df = 13); WT vs. apoA–I Δ190–243
(P = 0.0003, t = 4.951, df = 13), ac-apoA–I vs. Δ190-243 (P = 0.2614, t = 1.208,
df = 8). K. pneumoniae unpaired t-test: WT vs. ac-apoA–I (P = 0.0011, t = 4.285,
df = 12), WT vs Δ190–243 (P = 0.0083, t = 3.155, df = 12), ac vs. Δ190–243
(P = 0.2091, t = 1.496, df = 4).
1509W.H.J. Beck et al. / Biochimica et Biophysica Acta 1828 (2013) 1503–1510in part, to differences in recognition of the expressed O-antigen present
on the bacterial surface. Previous studies have reported that apoA–I
anti-microbial activity is partially mediated by its ability to discern the
O-antigen component of bacterial pathogens [36]. In addition, studies
with apoLp-III have shown that the apolipoproteins can recognize the
carbohydrate portion of LPS, although this interaction is weaker com-
pared to complete LPS [34].
Upon incubation with LPS, apoA–I displayed signiﬁcant changes
in electrophoretic mobility under non-denaturing conditions, indi-
cating binding interaction between the protein and LPS. The altered
electrophoresis properties may have resulted from changes in size
and overall net charge of newly formed protein-LPS complexes.
Such complexes have been characterized for apoLp-III, and consist
of 3 to 4 apolipoproteins and 9 to 24 LPS molecules, depending on
the LPS source [34]. The LPS-induced change in PAGE mobility was
reduced for apoA–IΔ190–243, while addition of LPS to ac-apoA–I
did not alter the electrophoretic mobility of the protein. Dot blot
analysis showed a decrease in LPS binding for ac-apoA–I and, to a
lesser extent, for apoA–IΔ190–243. The interaction of apoA–I
with LPS was further analyzed by measuring structural changes of
apoA–I and variants due to LPS binding interaction. It was shown
previously that apoA–I undergoes partial unfolding in certain
α-helical regions in the presence of LPS [37]. In the current study
we also observed a decreased α-helical content of WT apoA–I upon
LPS binding. This implies a structural reorganization of the apolipo-
protein induced by LPS, although we have no information about
the exact nature of this change. Ac-apoA–I displayed virtually no
change in α-helical content when incubated in the presence of LPS,
whereas apoA–I Δ190–243 showed changes in secondary structure
but to a lesser degree compared to WT apoA–I. Likewise, assessment
of changes in the exposure of hydrophobic regions by ANS ﬂuores-
cence revealed similar trends among WT and apoA–I variants. The
increased ANS binding to apoA–I in the presence of LPS again
indicate structural changes in apoA–I induced by LPS. Analysis of
the tryptophan emission spectra revealed a similar pattern. The
observed trends in LPS binding among the apoA–I variants reveal
that electrostatic interactions contribute signiﬁcantly to the abilityof apoA–I to bind with LPS, and that such interactions may occur
between the lysine ε-amino groups and the negatively charged
moieties of the lipid A region. Similar binding interactions have
also been reported for HDL, which has been shown to interact with
phosphate groups and the diglucosamine backbone of LPS [38]. The
C-terminal domainmay be at least partly responsible for LPS binding,
although LPS binding was not completely lost upon removal of the
C-terminal domain. This suggests that also a part of the N-terminal
core domain is capable of LPS binding, presumably because of the
amphipathic character of the α-helices. It was recently shown that
a fragment comprising amino acid residues 148–243 may harbor
the site that is responsible for the neutralization of LPS toxicity [37].
A comparison of protein interactions with PC or PG LUVs showed
that apoA–I displayed a strong preference for PG. Binding activity,
as measured by the ability to release calcein from bilayer vesicles,
was approximately 1000 times higher for when the LUVs were
made from PG compared to PC. This result may point out that
apoA–I is able to discriminate between PC-rich mammalian mem-
branes and bacterial membranes containing signiﬁcant amounts of
PG. Thus it seems apparent that apoA–I utilizes electrostatic forces
to differentiate between host and pathogenic cells. However, ganglio-
sides present in the mammalian membrane also provides a net nega-
tive charge. Therefore, charge distribution on the apolipoprotein
surface may be required for membrane speciﬁcity. The apoA–I vari-
ants displayed similar trends in activity among interactions with PG
vesicles compared to LPS binding. Upon acetylation, the ability of
apoA–I to release calcein from PG vesicles was signiﬁcantly reduced.
It is interesting to note that, although apoA–I contains roughly an
equal amount of lysine and arginine residues (21 and 16, respectively),
neutralization of lysine residues alone resulted in a major decline in ac-
tivity. Removal of the C-terminal domain reduced the ability to release
calcein, although the deletionmutant remained active. It seems reason-
able to conclude that charge–charge interactions are the main driving
force for apoA-I to bind to PG membranes, which is similar to that ob-
served for apoLp-III [39]. Similar to LPS binding, the N-terminal domain
of apoA–I contributes to the PG binding activity. In contrast, previous
studies showed that the conversion of PC vesicles by apoA–IΔ190–243
into discoidal lipid-protein complexes was greatly reduced [23,40].
However, the present study showed that while reduction in activity
was observed, the protein remained active for PG vesicles.
It cannot be excluded that unforeseen structural changes in the pro-
tein variants tested here affected the LPS and PG binding. Acetylation
decreased theα-helical content, although the extent was less than pre-
viously reported [41]. Lipid binding, measured by the conversion of PC
vesicles into discoidal complexes, was hardly affected [41]. In addition,
the present study showed that the protein stability was retained upon
acetylation. Removal of ~50 C-terminal amino acid residues could po-
tentially affect the structure in the remaining protein. However, the
C-terminal domain may be unstructured in the lipid-free form of the
protein and thus the deletionwill probably not affect the core structure.
This explains why WT and apoA–I Δ190–243 display a similar protein
stability [40,42]. In any event, structure-guided site-directed mutagen-
esis will be a necessary tool to pinpoint the exact regions in the protein
responsible for the membrane interaction.
The results of the present study, taken together, suggest that ionic
forces predominately contribute to the binding interaction with
LPS and PG bilayer vesicles. Electrostatic interactions between the
ε-amino groups of lysine side chains may initiate binding with nega-
tively charged phosphate moieties on LPS, after which the amphi-
pathic character of apoA–I facilitates binding to the hydrophobic
portion of LPS. PG, which is abundantly present in the inner mem-
brane of the bacteria, may then recruit apoA–I to the surface leading
to membrane destabilization, further contributing to the bacteriostatic
properties of apoA–I.
Gram-negative bacterial infections present a major concern in the
healthcare ﬁeld, accounting for approximately 70% of hospital-acquired
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tions [43]. In addition, the increasing resistance of these organisms to
traditional antibiotics and the decline in the development of novel ther-
apeutics has created a pressing need to explore alternative strategies. In
recent years, apoA–I has garnered recognition for its ability to exert
anti-microbial properties and inhibit bacterial sepsis by neutralizing
LPS. In addition, apoA–I exhibits virtually none of the toxic effects,
which are typically associated with other anti-microbial peptides, mak-
ing it an advantageous alternative to current methods of treatment
against gram-negative bacterial infections.Acknowledgements
Thisworkwas funded by grants from theNational Institutes ofHealth
(NIH) to P.M.M.W (SC3GM089564) and E.J.H-S (SC3GM092298) and the
NIH Research Initiative for Scientiﬁc Enhancement (RISE) Program
(5R25GM071638). The authors thank Dr. Yuan Yu Lee, Center for
Education in Proteomics Analysis at CSU Long Beach, for mass spectro-
metric analysis.References
[1] A.R. Tall, Cholesterol efﬂux pathways and other potential mechanisms involved in
the athero-protective effect of high density lipoproteins, J. Intern. Med. 263
(2008) 256–273.
[2] I. Martin, M.C. Dubois, T. Saermark, J.M. Ruysschaert, Apolipoprotein A-1 interacts
with the N-terminal fusogenic domains of SIV (simian immunodeﬁciency virus)
GP32 and HIV (human immunodeﬁciency virus) GP41: implications in viral
entry, Biochem. Biophys. Res. Commun. 186 (1992) 95–101.
[3] N. Tada, T. Sakamoto, A. Kagami, K. Mochizuki, K. Kurosaka, Antimicrobial activity
of lipoprotein particles containing apolipoprotein Al, Mol. Cell. Biochem. 119
(1993) 171–178.
[4] A.M. Shiﬂett, J.R. Bishop, A. Pahwa, S.L. Hajduk, Human high density lipoproteins
are platforms for the assembly of multi-component innate immune complexes,
J. Biol. Chem. 280 (2005) 32578–32585.
[5] A.P. Hubsch, A.T. Casas, J.E. Doran, Protective effects of reconstituted high-density
lipoprotein in rabbit gram-negative bacteremia models, J. Lab. Clin. Med. 126
(1995) 548–558.
[6] D.M. Levine, T.S. Parker, T.M. Donnelly, A. Walsh, A.L. Rubin, In vivo protection
against endotoxin by plasma high density lipoprotein, Proc. Natl. Acad. Sci. U. S. A.
90 (1993) 12040–12044.
[7] T. Imai, T. Fujita, Y. Yamazaki, Beneﬁcial effects of apolipoprotein A–I on
endotoxemia, Surg. Today 33 (2003) 684–687.
[8] D. Pajkrt, J.E. Doran, F. Koster, P.G. Lerch, B. Arnet, T. van der Poll, J.W. ten Cate, S.J.
van Deventer, Antiinﬂammatory effects of reconstituted high-density lipoprotein
during human endotoxemia, J. Exp. Med. 184 (1996) 1601–1608.
[9] T. Massamiri, P.S. Tobias, L.K. Curtiss, Structural determinants for the interaction
of lipopolysaccharide binding protein with puriﬁed high density lipoproteins:
role of apolipoprotein A-I, J. Lipid Res. 38 (1997) 516–525.
[10] J.H. Levels, P.R. Abraham, A. van den Ende, S.J. van Deventer, Distribution and ki-
netics of lipoprotein-bound endotoxin, Infect. Immun. 69 (2001) 2821–2828.
[11] P. Thaveeratitham, W. Plengpanich, W. Naen-Udorn, S. Patumraj, W. Khovidhunkit,
Effects of human apolipoprotein A–I on endotoxin-induced leukocyte adhesion on
endothelial cells in vivo and on the growth of Escherichia coli in vitro, J. Endotoxin
Res. 13 (2007) 58–64.
[12] K. Emancipator, G. Csako, R.J. Elin, In vitro inactivation of bacterial endotoxin by
human lipoproteins and apolipoproteins, Infect. Immun. 60 (1992) 596–601.
[13] J. Ma, X.L. Liao, B. Lou, M.P. Wu, Role of apolipoprotein A–I in protecting against
endotoxin toxicity, Acta Biochim. Biophys. Sin. (Shanghai) 36 (2004) 419–424.
[14] J.A. Morrow, M.L. Segall, S. Lund-Katz, M.C. Phillips, M. Knapp, B. Rupp, K.H.
Weisgraber, Differences in stability among the human apolipoprotein E isoforms de-
termined by the amino-terminal domain, Biochemistry 39 (2000) 11657–11666.
[15] B.N. Ames, Assay of inorganic phosphate, total phosphate and phosphatases,
Methods Enzymol. 8 (1966) 115–118.
[16] C.R. Raetz, C. Whitﬁeld, Lipopolysaccharide endotoxins, Annu. Rev. Biochem. 71
(2002) 635–700.
[17] H. Saito, S. Lund-Katz, M.C. Phillips, Contributions of domain structure and lipid
interaction to the functionality of exchangeable human apolipoproteins, Prog.
Lipid Res. 43 (2004) 350–380.[18] H. Saito, P. Dhanasekaran, D. Nguyen, P. Holvoet, S. Lund-Katz, M.C. Phillips,
Domain structure and lipid interaction in human apolipoproteins A–I and E, a
general model, J. Biol. Chem. 278 (2003) 23227–23232.
[19] D.P. Rogers, L.M. Roberts, J. Lebowitz, J.A. Engler, C.G. Brouillette, Structural anal-
ysis of apolipoprotein A–I: effects of amino- and carboxy-terminal deletions on
the lipid-free structure, Biochemistry 37 (1998) 945–955.
[20] L. Stryer, The interaction of a naphthalene dye with apomyoglobin and
apohemoglobin. A ﬂuorescent probe of non-polar binding sites, J. Mol. Biol. 13
(1965) 482–495.
[21] A. Leroy, A. Jonas, Native-like structure and self-association behavior of apolipoprotein
A–I in a water/n-propanol solution, Biochim. Biophys. Acta 1212 (1994) 285–294.
[22] C.G. Brouillette, G.M. Anantharamaiah, J.A. Engler, D.W. Borhani, Structural
models of human apolipoprotein A–I: a critical analysis and review, Biochim.
Biophys. Acta 1531 (2001) 4–46.
[23] W.S. Davidson, T. Hazlett, W.W. Mantulin, A. Jonas, The role of apolipoprotein
AI domains in lipid binding, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
13605–13610.
[24] H.L. Zhu, D. Atkinson, Conformation and lipid binding of a C-terminal (198–243)
peptide of human apolipoprotein A–I, Biochemistry 46 (2007) 1624–1634.
[25] M. Tanaka, P. Dhanasekaran, D. Nguyen, S. Ohta, S. Lund-Katz, M.C. Phillips, H.
Saito, Contributions of the N- and C-terminal helical segments to the lipid-free
structure and lipid interaction of apolipoprotein A–I, Biochemistry 45 (2006)
10351–10358.
[26] V. Narayanaswami, R.S. Kiss, P.M.M. Weers, The helix bundle: a reversible lipid
binding motif, Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 155 (2010)
123–133.
[27] C.R. Raetz, W. Dowhan, Biosynthesis and function of phospholipids in Escherichia
coli, J. Biol. Chem. 265 (1990) 1235–1238.
[28] V. Teixeira, M.J. Feio, M. Bastos, Role of lipids in the interaction of antimicrobial
peptides with membranes, Prog. Lipid Res. 51 (2012) 149–177.
[29] Y. Kaconis, I. Kowalski, J. Howe, A. Brauser, W. Richter, I. Razquin-Olazaran, M.
Inigo-Pestana, P. Garidel, M. Rossle, G. Martinez de Tejada, T. Gutsmann, K.
Brandenburg, Biophysical mechanisms of endotoxin neutralization by cationic
amphiphilic peptides, Biophys. J. 100 (2011) 2652–2661.
[30] H. Jenssen, P. Hamill, R.E. Hancock, Peptide antimicrobial agents, Clin. Microbiol.
Rev. 19 (2006) 491–511.
[31] L.D. Johnston, G. Brown, D. Gauthier, K. Reece, H. Kator, P. Van Veld, Apolipoprotein
A–I from striped bass (Morone saxatilis) demonstrates antibacterial activity in vitro,
Comp. Biochem. Physiol. B: Biochem. Mol. Biol. 151 (2008) 167–175.
[32] S.M. Gordon, S. Hofmann, D.S. Askew, W.S. Davidson, High density lipoprotein:
it's not just about lipid transport anymore, Trends Endocrinol. Metab. 22 (2011)
9–15.
[33] M. Van Oosten, P.C. Rensen, E.S. Van Amersfoort, M. Van Eck, A.M. Van Dam,
J.J. Breve, T. Vogel, A. Panet, T.J. Van Berkel, J. Kuiper, Apolipoprotein E
protects against bacterial lipopolysaccharide-induced lethality. A new thera-
peutic approach to treat gram-negative sepsis, J. Biol. Chem. 276 (2001)
8820–8824.
[34] M. Oztug, D. Martinon, P.M.M. Weers, Characterization of the apoLp-III/LPS
complex: insight into the mode of binding interaction, Biochemistry 51 (2012)
6220–6227.
[35] A. Zdybicka-Barabas, M. Cytrynska, Involvement of apolipophorin III in antibacterial
defense of Galleria mellonella larvae, Comp. Biochem. Physiol. B: Biochem. Mol. Biol.
158 (2011) 90–98.
[36] M. Biedzka-Sarek, J. Metso, A. Kateiﬁdes, T. Meri, T.S. Jokiranta, A. Muszynski,
J. Radziejewska-Lebrecht, V. Zannis, M. Skurnik, M. Jauhiainen, Apolipoprotein A–I
exerts bactericidal activity against Yersinia enterocolitica serotype O:3, J. Biol.
Chem. 286 (2011) 38211–38219.
[37] M.F. Henning, V. Herlax, L. Bakas, Contribution of the C-terminal end of apolipoprotein
AI to neutralization of lipopolysaccharide endotoxic effect, Innate Immun. 17 (2011)
327–337.
[38] K. Brandenburg, G. Jurgens, J. Andra, B. Lindner, M.H. Koch, A. Blume, P. Garidel,
Biophysical characterization of the interaction of high-density lipoprotein
(HDL) with endotoxins, Eur. J. Biochem. 269 (2002) 5972–5981.
[39] L.J. Vasquez, G.E. Abdullahi, C.P. Wan, P.M.M. Weers, Apolipophorin III lysine
modiﬁcation: effect on structure and lipid binding, Biochim. Biophys. Acta 1788
(2009) 1901–1906.
[40] M. Tanaka, M. Koyama, P. Dhanasekaran, D. Nguyen, M. Nickel, S. Lund-Katz, H.
Saito, M.C. Phillips, Inﬂuence of tertiary structure domain properties on the func-
tionality of apolipoprotein A–I, Biochemistry 47 (2008) 2172–2180.
[41] G. Brubaker, D.Q. Peng, B. Somerlot, D.J. Abdollahian, J.D. Smith, Apolipoprotein
A–I lysine modiﬁcation: effects on helical content, lipid binding and cholesterol
acceptor activity, Biochim. Biophys. Acta 1761 (2006) 64–72.
[42] X. Mei, D. Atkinson, Crystal structure of C-terminal truncated apolipoprotein A-I
reveals the assembly of high density lipoprotein (HDL) by dimerization, J. Biol.
Chem. 286 (2011) 38570–38582.
[43] A.Y. Peleg, D.C. Hooper, Hospital-acquired infections due to gram-negative bacteria,
N. Engl. J. Med. 362 (2010) 1804–1813.
